Current Status and Future of Antifungal Therapy for Systemic Mycoses

Author(s): Joshua D. Nosanchuk

Journal Name: Recent Patents on Anti-Infective Drug Discovery
Continued as Recent Advances in Anti-Infective Drug Discovery

Volume 1 , Issue 1 , 2006

Become EABM
Become Reviewer
Call for Editor


Since the 1950s there has been an increase in the incidence of invasive fungal disease. The first successful systemically administered antifungal drug, amphotericin B, was introduced in the 1950s and, until very recently, was considered the best therapeutic drug for severe mycoses. The development of new antifungals to treat systemic disease has been slow compared to that of antibacterial compounds, with the introduction of only a single new class of drugs over the past 20 years. This review discusses the antifungal drugs that are clinically in use and summarizes interesting new applications and patents from the US Patent and Trademark Office.

Keywords: Fungi, antifungal, combination therapy, antibody

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [75 - 84]
Pages: 10
DOI: 10.2174/157489106775244109

Article Metrics

PDF: 20